Table 3.
Treatment-related toxicity
| NCI-CTC adverse event | Grade (cases: WBRT/WBRT +erlotinib)
|
|||||
|---|---|---|---|---|---|---|
| Any | 1 | 2 | 3 | 4 | 5 | |
| Constitutional symptoms | ||||||
| Acratia | 15/12 | 12/9 | 3/3 | |||
| Fatigue | 3/3 | 3/3 | ||||
| Weight loss | 13/12 | 11/10 | 2/2 | |||
| Dermatology | ||||||
| Cheilitis | 0/0 | 1/9 | ||||
| Dry skin | 1/9* | 0/3 | 0/1 | |||
| Nail changes | 0/4* | 0/9 | ||||
| Pruritus/itching | 0/9* | 0/9 | 0/4 | |||
| Rash | 0/13* | 4/5 | ||||
| Radiation dermatitis | 4/5 | |||||
| Gastrointestinal | ||||||
| Anorexia | 8/13* | 2/5 | 2/6 | 0/2 | ||
| Constipation | 8/10 | 8/8 | 0/2 | |||
| Diarrhea | 1/3 | 1/3 | ||||
| Dyspepsia | 1/3 | 1/3 | ||||
| Nausea | 7/11* | 6/7 | 1/4 | |||
| Vomiting | 5/6 | 1/4 | 0/2 | |||
| Mucositis | 1/1 | 1/1 | ||||
| Stomatitis | 1/2 | 1/2 | ||||
| Taste alteration | 3/3 | 3/3 | ||||
| Eyes | ||||||
| Xerophthalmia | 0/0 | |||||
| Conjunctivitis | 0/0 | |||||
| Headache | 6/5 | 5/1 | 1/4 | |||
| Dizziness | 6/11* | 5/10 | 0/0 | 1/1 | ||
| Pulmonary/upper respiratory | ||||||
| Cough | 5/8 | 5/7 | 0/1 | |||
| Dyspnea | 0/0 | |||||
| Pneumonitis | 7/7 | 7/7 | ||||
| Blood | ||||||
| Hemoglobin | 2/5 | 2/5 | ||||
| Leucocyte | 3/3 | 3/3 | ||||
| Platelet | 2/2 | 2/2 | ||||
| Liver/renal function | ||||||
| AST | 2/4 | 2/2 | 0/2 | |||
| ALT | 2/3 | 2/3 | ||||
| Bilirubin | 1/0 | 1/0 | ||||
| Serum creatinine | 2/2 | 2/2 | ||||
Note:
*
P < 0.05.
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; NCI-CTC, National Cancer Institute-Common Toxicity Criteria; WBRT, whole brain radiotherapy.